KOLMAR-BNH
22.4.2024 05:00:33 CEST | Business Wire | Press release
Hemohim is garnering remarkable popularity in the global market as Korea's one of the leading functional foods.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418277251/en/
Kolmar BNH Sejong Factory (Photo: Kolmar BNH)
Hemohim is developed through an eight-year collaboration between Kolmar BNH (KOSDAQ: 200130) and the Korea Atomic Energy Research Institute, with an investment of KRW 5 billion. It was extracted from raw materials of angelica gigas, cnidium officinale, and paeonia japonica, which have been traditionally used in herbal medicine. Kolmar BNH performed tests on humans to confirm the safety and efficacy of its main ingredient, ‘HemoHIM Extract complex of Angelica gigas, etc.’, and was recognized by the Ministry of Food and Drug Safety of Korea in 2006 for its immune-boosting properties.
Distributed by Atomy, a customer of Kolmar BNH, Hemohim has sold over KRW 2 trillion worth of products in just 17 years since its launch, making it the nation’s best-selling individually approved health functional food. With strong demand from many countries like Australia, the US, and Thailand, Hemohim has expanded its global presence to over 20 countries.
Following a rigorous review process, Hemohim received approval from the Korean Ministry of Food and Drug Safety as the nation’s first individually approved health supplement product designed to enhance immune function.
Ranking the second-highest exported product after red ginseng in Korea, Hemohim is the leading individually approved health functional food ingredient. Kolmar BNH, propelled by Hemohim's success, was honored with the '200 Million Dollar Export Tower' at the 2021 'Trade Day' ceremony hosted by the Korea International Trade Association.
Kolmar BNH is making R&D efforts to sharpen its material competitiveness, as evidenced by the 'Hemohim Sustaining Technology Development Project.' After six years of endeavors, it obtained a fatigue recovery function last year, solidifying Hemohim's status as a dual-functional food with immune enhancement and fatigue recovery.
To further reach the European market, Kolmar BNH has developed HemohimG, tailored to suit European preferences in tastes and aroma. HemohimG is a product made for exports that follow the food regulations of each country. It is now poised for export to the UK and Turkey.
A Kolmar BNH official stated, "Hemohim represents Korea's top health functional food, backed by research capabilities and manufacturing prowess. After its success in Korea over the past 16 years, Hemohim is ready to leave its footprint on the global market."
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418277251/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hisense Delivers 38% Sales Uplift in Western Europe Markets With NIQ’s AI-Powered Market Intelligence6.5.2026 05:00:00 CEST | Press release
NIQ insights drive international expansion and measurable growth for Hisense across key global markets NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new learnings from its long-standing collaboration with Hisense, a leading global brand in home appliances and smart technologies. Using NIQ’s AI‑powered market intelligence, Hisense has accelerated international expansion, improved local market decision-making, and delivered measurable growth across more than 20 key markets and 12+ categories. The case study demonstrates how AI‑driven insights help global brands move faster, localize better, and compete more effectively in complex markets. The Challenge As Hisense expanded internationally, it faced rising complexity across global markets. Consumer preferences differed sharply across regions such as Western Europe, Eastern Europe, and Latin America, making a one‑size‑fits‑all approach ineffective. NIQ’s AI‑powered intelligence delivered the local market depth need
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 01:00:00 CEST | Press release
Phase 1 study has demonstrated pharmacokinetics (PK) equivalence between SB27 and KeytrudaPhase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sour
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 00:00:00 CEST | Press release
Megaport DDoS Protection removes the trade-off between security, performance, and cost, offering rapid enterprise-grade mitigation. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing s
IFF Reports First Quarter 2026 Results5.5.2026 22:23:00 CEST | Press release
Delivered solid top and bottom line Q1 resultsProgressing disciplined sale process for Food Ingredients businessReaffirms Full Year 2026 Financial Guidance IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks t
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 22:06:00 CEST | Press release
Strong FY 2026 Demonstrates Strategy and Operating Principles Are Delivering SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom